2. Composition of Certain Balance Sheet Items

Inventory

The composition of inventory was as follows:

	September 30,			December 31,
	2016			2015
	(in thousands)
Raw materials	$	2,866		$	2,141
Work in progress		3			3
Finished goods		2,438			2,338
Total inventory		5,307			4,482
Less strategic inventory classified as non-current		(2,980	)		(2,800	)
Total inventory classified as current	$	2,327		$	1,682

We have one manufacturer for mifepristone, the active pharmaceutical ingredient (API) in Korlym — Produits Chimiques Auxiliaires et de Synthèse SA (PCAS) — and one tablet manufacturer for Korlym — Alcami Corporation (formerly known as AAI Pharma Services Corp.). If either of these companies is unable to manufacture API or Korlym tablets in the quantities and time frames we require, we may not be able to meet customer demand. In order to mitigate these risks, we purchase and hold as “Strategic Inventory” additional quantities of API and Korlym tablets that we do not expect to consume within 12 months following the relevant balance sheet date.

Other Accrued Liabilities

Other accrued liabilities consisted of the following:

	September 30,		December 31,
	2016		2015
	(in thousands)
Government rebates	$	2,787	$	1,663
Accrued compensation		3,380		1,103
Commercialization costs		89		111
Legal fees		140		69
Professional fees		146		220
Other		332		91
Total other accrued liabilities	$	6,874	$	3,257